Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.62 |
| ▸ | MC4R | P32245 | 15/20 | 0.61 |
| ▸ | MC1R | Q01726 | 11/20 | 0.61 |
| ▸ | MC5R | P33032 | 1/20 | 0.57 |
| ▸ | MC3R | P41968 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188828 | 0.91 | MC4R (0.68) | MC4RMC1RMC5RMC3R | |
| SCHEMBL26006253 | 0.88 | KISS1R (0.64) | KISS1RMC4RMC1RMC5RMC3R | |
| SCHEMBL29359331 | 0.88 | KISS1R (0.64) | KISS1RMC4RMC1RMC5RMC3R | |
| SCHEMBL26006274 | 0.88 | KISS1R (0.64) | KISS1RMC4RMC1RMC5RMC3R | |
| SCHEMBL13035278 | 0.88 | MC4R (0.68) | MC4RMC1RMC5RMC3R | |
| SCHEMBL30494060 | 0.87 | KISS1R (0.60) | KISS1RMC4RMC1R | |
| SCHEMBL29398150 | 0.86 | KISS1R (0.65) | KISS1RMC4R | |
| SCHEMBL30366588 | 0.84 | KISS1R (0.60) | KISS1RMC4R | |
| SCHEMBL29519296 | 0.84 | KISS1R (0.60) | KISS1RMC4R | |
| SCHEMBL14215855 | 0.82 | MC4R (0.59) | MC4RMC1RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260092056-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS | LG CHEMICAL LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12590305-B2 | Complement component C5 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | EPITRACKER INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-11254740-B2 | Methods of treatment using IL-23p19 monoclonal antibodies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3953327-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2022-02-16 | — | — | EP | disclosed |
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |
| US-11248037-B2 | Multivalent heteromultimer scaffold design and constructs | ZYMEWORKS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | KISS1R 586/4885MC4R 616/4885MC1R 640/4885 |
| US-20260077012-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | CD4, COL2A1, MMP1 | KISS1R 3095/4885MC4R 3669/4885MC1R 992/4885 |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | KISS1R 4274/4885MC4R 3054/4885MC1R 1399/4885 |
| US-12590305-B2 | Complement component C5 iRNA compositions and methods of use thereof | UPF1, C5, NSUN2 | KISS1R 4818/4885MC4R 4775/4885MC1R 2566/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | KISS1R 297/4885MC4R 455/4885MC1R 601/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | KISS1R 3677/4885MC4R 1730/4885MC1R 1434/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | KISS1R 286/4885MC4R 2077/4885MC1R 3454/4885 |
| US-20260092056-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS | MC5R, MC4R, MC3R | KISS1R 46/4885MC4R 2/4885MC1R 5/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | KISS1R 1564/4885MC4R 2222/4885MC1R 476/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | KISS1R 2445/4885MC4R 222/4885MC1R 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.